Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Kite, a Gilead Company (NASDAQ:GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).– Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study –
– 對於復發/難治性多發性骨髓瘤患者的Anito-電芯在第1和iMMagine-1研究中持續可管理的安全性和持久性響應將由合作伙伴Arcellx進行展示；緊隨第3期iMMagine-3研究中第一位患者用藥的進展 –
– Survival Rate for Yescarta Supported by Largest Real-World Analysis of CAR T for Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma –
– Yescarta的存活率得到了CAR T在復發/難治性大b-細胞淋巴瘤二線治療中最大規模實際分析的支持 –
– Durability of Response and Long-Term Survival with Yescarta and Tecartus in Multiple Blood Cancers Observed in ZUMA-5, ZUMA-2, and ZUMA-3 Studies –
– 在ZUMA-5、ZUMA-2和ZUMA-3研究中發現Yescarta和Tecartus在多種血液癌症中的持久反應和長期存活 –
Kite, a Gilead Company (NASDAQ:GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).
蓋利德公司（納斯達克：GILD）的Kite將分享18個報告，其中包括六個口頭報告，展示其CAR T細胞療法組合在一系列血液癌症中的實力，這將在第66屆美國血液學會（ASH）年會暨博覽會（12月7-10日）期間展示。
譯文內容由第三人軟體翻譯。
